Literature DB >> 15808314

Thermonuclease gene as a target for specific identification of Staphylococcus intermedius isolates: use of a PCR-DNA enzyme immunoassay.

Karsten Becker1, Christof von Eiff, Birgit Keller, Michaela Brück, Jerome Etienne, Georg Peters.   

Abstract

A PCR-DNA enzyme immunoassay (PCR-DEIA) was developed for identification of the coagulase-positive species Staphylococcus intermedius. Two PCR primers and a hybridization probe were designed to target specific sequences of the S. intermedius thermonuclease (nuc) gene. In addition to S. intermedius reference strains, the PCR-DEIA was tested using 295 veterinary and human S. intermedius isolates. A specific 933-bp DNA fragment was successfully amplified in 281 (94.9%) S. intermedius isolates. Five canine isolates showed an unexpected 2.8-kbp band. Except for 10 amplicons derived from equine, camel, and pigeon isolates, all positive PCR results (n = 288, 96.6%) were confirmed by the colorimetric microtiter plate DEIA hybridization. Isolates that failed both in amplification and DEIA hybridization were only observed in equine isolates (10/23, 43.5%). Except for the limitations with isolates of hoofed animals, the S. intermediusnuc PCR assay has potential for rapid identification of S. intermedius and differentiation from other coagulase-positive staphylococci including S. aureus.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15808314     DOI: 10.1016/j.diagmicrobio.2004.11.010

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  7 in total

1.  Does nasal cocolonization by methicillin-resistant coagulase-negative staphylococci and methicillin-susceptible Staphylococcus aureus strains occur frequently enough to represent a risk of false-positive methicillin-resistant S. aureus determinations by molecular methods?

Authors:  Karsten Becker; Isabelle Pagnier; Brigitte Schuhen; Frauke Wenzelburger; Alexander W Friedrich; Frank Kipp; Georg Peters; Christof von Eiff
Journal:  J Clin Microbiol       Date:  2006-01       Impact factor: 5.948

2.  In vitro activity against Staphylococcus aureus of a novel antimicrobial agent, PRF-119, a recombinant chimeric bacteriophage endolysin.

Authors:  Evgeny A Idelevich; Christof von Eiff; Alexander W Friedrich; Domenico Iannelli; Guoqing Xia; Georg Peters; Andreas Peschel; Ingrid Wanninger; Karsten Becker
Journal:  Antimicrob Agents Chemother       Date:  2011-07-11       Impact factor: 5.191

3.  eap Gene as novel target for specific identification of Staphylococcus aureus.

Authors:  Muzaffar Hussain; Christof von Eiff; Bhanu Sinha; Insa Joost; Mathias Herrmann; Georg Peters; Karsten Becker
Journal:  J Clin Microbiol       Date:  2007-12-19       Impact factor: 5.948

4.  Reclassification of phenotypically identified staphylococcus intermedius strains.

Authors:  Takashi Sasaki; Ken Kikuchi; Yoshikazu Tanaka; Namiko Takahashi; Shinichi Kamata; Keiichi Hiramatsu
Journal:  J Clin Microbiol       Date:  2007-06-27       Impact factor: 5.948

5.  Susceptibility in vitro of canine methicillin-resistant and -susceptible staphylococcal isolates to fusidic acid, chlorhexidine and miconazole: opportunities for topical therapy of canine superficial pyoderma.

Authors:  S M Clark; A Loeffler; R Bond
Journal:  J Antimicrob Chemother       Date:  2015-03-05       Impact factor: 5.790

6.  Genetic resistance determinants to fusidic acid and chlorhexidine in variably susceptible staphylococci from dogs.

Authors:  S-M Frosini; R Bond; M Rantala; T Grönthal; S C Rankin; K O'Shea; D Timofte; V Schmidt; J Lindsay; A Loeffler
Journal:  BMC Microbiol       Date:  2019-04-25       Impact factor: 3.605

7.  Investigations on the efficacy of routinely used phenotypic methods compared to genotypic approaches for the identification of staphylococcal species isolated from companion animals in Irish veterinary hospitals.

Authors:  Lisa Geraghty; Mary Booth; Neil Rowan; Andrew Fogarty
Journal:  Ir Vet J       Date:  2013-05-01       Impact factor: 2.146

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.